Showing 51-60 of 228 results for "".
Your Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/21135/Make Some Noise: Advocating for Access
https://practicaldermatology.com/topics/practice-management/make-some-noise-advocating-for-access/20401/DCAN seeks to improve access to dermatologic treatments.About Face: Longer Shifts for Residents; Residents of Distinction Honored; Ask an Expert: Managing PIH
https://practicaldermatology.com/youngmd-connect/resident-resource-center/about-face-longer-shifts-for-residents-residents-of-distinction-honored-ask-an-expert-managing-pih/20716/Managing Pruritus in Geriatric Patients
https://practicaldermatology.com/topics/practice-management/managing-pruritus-in-geriatric-patients/21146/Treatment tips and considerations for this patient population.Psoriasis Wish List
https://practicaldermatology.com/topics/psoriasis/psoriasis-wish-list/20667/Clinical thought leaders share what they hope for to improve treatment in the future.Ask An Expert: Establish Your Expertise
https://practicaldermatology.com/youngmd-connect/resident-resource-center/ask-an-expert-establish-your-expertise/21174/The Next Best Thing
https://practicaldermatology.com/youngmd-connect/resident-resource-center/the-next-best-thing/23521/Virtual rotations can help fill a void in the COVID-19 era.Getting The Red Out: Expert Tips
https://practicaldermatology.com/topics/practice-management/getting-the-red-out-expert-tips/20701/Dermatologists share their go-to approaches for reducing facial redness in rosacea.Currents: Patient Engagement And Adherence
https://practicaldermatology.com/topics/practice-management/currents-patient-engagement-and-adherence/23500/Eczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, and